Cure My Disease

Don't miss your cure!

 Log in / Sign up

Massive european study aims to redefine success in liver transplants

NCT ID NCT07585890

Knowledge-focused Sponsor: University Medical Center Groningen Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 04, 2026 · Updated 2 times

Summary

This study is collecting information from 10,000 liver transplant patients across Europe to create a new, up-to-date reference for what good outcomes look like when using machine perfusion (a technique that keeps donated livers healthier before transplant). The goal is to help doctors better understand which preservation methods work best for different patients and donor livers. Participants are adults receiving a liver transplant, and the study simply observes their recovery without testing any new treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 10,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2026

Expected to finish

Dec 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

All postmortal livers accepted (transplanted and not-transplanted after machine perfusion) upon organ offer between 01.01.2021 and 31.12.2025 for patients \>18 years at the time of liver transplantation.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * All postmortal livers accepted (transplanted and not-transplanted after machine perfusion) upon organ offer for patients \>18 years at the time of liver transplantation. * All donor types (DBD, DCD) * Preservation either with static cold storage alone or combined with machine perfusion (MP). * Donor livers underwent MP as part of routine clinical practice and the choice of perfusion protocol was made according to institutional standard practice. * Eligible MP protocols are: 1. end-ischemic single- or dual hypothermic oxygenated MP \[e(D)HOPE\], 2. end-ischemic (back-to-base) normothermic MP \[eNMP\], 3. continuous (device-to-donor) normothermic MP \[cNMP\], 4. e(D)HOPE followed by controlled oxygenated rewarming and normothermic MP \[e(D)HOPE-COR-NMP)\], 5. e(D)HOPE followed by normothermic MP \[e(D)HOPE-NMP\], or 6. Normothermic regional perfusion followed by SCS or an ex situ MP protocol. * A minimum follow-up of 12 months after liver transplantation is required. Exclusion Criteria: * Livers that were allocated to a MP protocol as part of a prospective randomized or interventional clinical trial comparing different preservation techniques or any other invention. * Living donor liver transplantation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute liver failure are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute liver failure chronic liver failure cirrhosis of liver End Stage Liver Disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute liver failure End-stage liver disease (ESLD) Liver cirrhosis Liver transplantation

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    9 sites in 8 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • A.O.U. Città della Salute e della Scienza

    RECRUITING

    Torino, Italy

  • Karolinska Institutet

    NOT_YET_RECRUITING

    Stockholm, Sweden

  • King's College Hospital NHS Foundation Trust

    NOT_YET_RECRUITING

    London, United Kingdom

  • Medical University of Vienna

    NOT_YET_RECRUITING

    Vienna, Austria

  • Royal Free London NHS Foundation Trust

    NOT_YET_RECRUITING

    London, United Kingdom

  • University Hospital Basel

    NOT_YET_RECRUITING

    Basel, Switzerland

  • University Hospital Essen

    NOT_YET_RECRUITING

    Essen, Germany

  • University Hospitals Leuven

    NOT_YET_RECRUITING

    Leuven, Belgium

  • University Medical Center Groningen

    RECRUITING

    Groningen, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.